Xin Lang Cai Jing·2026-02-04 23:58Core Viewpoint - Despite positive policy progress, the implementation of the commercial insurance innovative drug directory faces challenges [2] Group 1: Current Status of Innovative Drugs - Currently, basic medical insurance covers 44% of innovative drug sales costs, while commercial insurance only covers 7%, leaving nearly half of the costs to be borne by patients or other channels [2] - The first version of the commercial insurance innovative drug directory was released by the National Medical Insurance Administration in December 2025, officially implemented on January 1, 2026, covering five CAR-T products, including Fosun Pharma's CAR-T product Yikaida [2] Group 2: Bottlenecks in Implementation - Three main bottlenecks need to be overcome for the effective implementation of the commercial insurance innovative drug directory: 1. Deepening the "three medical collaborations" to create a dual-channel mechanism of "medical insurance + commercial insurance" [2] 2. Optimizing the process and mechanism connections, enhancing cooperation between insurance companies and regulatory bodies [3] 3. Strengthening patient education and awareness through collaboration between medical and insurance institutions [3] Group 3: Focus on Elderly Major Diseases - The rapid growth of the elderly population is leading to an increase in age-related diseases, such as central nervous system diseases and rare diseases, while the number of innovative drug companies in this field is limited [3] - The importance of payment support for innovative drug development for elderly diseases is emphasized, suggesting the use of medical insurance data for research and development [3][4] Group 4: Recommendations for Policy and Funding - Recommendations include creating a special fund for elderly disease research and development, lowering R&D thresholds to attract more entrepreneurs and investors, and supporting the inclusion of innovative drugs for elderly diseases in basic medical insurance and commercial health insurance directories [4] - The establishment of a milestone reward system for projects entering clinical phase II is suggested to address challenges in the elderly health sector [4] Group 5: Company Strategy and Global Collaboration - Fosun Pharma is actively seeking global collaborations and has announced multiple business development transactions, indicating a recognition of China's innovative capabilities internationally [5] - The company focuses on core areas such as oncology, immune inflammation, and central nervous system diseases, utilizing diverse methods like licensing and collaborative development to enhance its pipeline and market presence [5]